规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
靶点 |
GLI1 ( IC50 = 5 μM )
|
|
---|---|---|
体外研究 (In Vitro) |
体外活性:GANT61 是 GLI1 以及 GLI2 诱导转录的抑制剂。 GANT61 抑制 GLI1 的 DNA 结合能力。 GANT61 抑制 Hedgehog 信号传导,IC50 为 5 μM,对其他途径表现出选择性,例如 TNF 信号传导/NFκB 激活、糖皮质激素受体基因反式激活和 Ras-Raf-Mek-Mapk 级联。 GANT61 以 GLI 依赖性方式有效抑制体外肿瘤细胞增殖。 GANT61 诱导慢性淋巴细胞白血病细胞 (CLL) 凋亡,但不诱导正常 B 淋巴细胞凋亡。 GANT61 在人结肠癌细胞系中诱导强大的细胞毒性并消除克隆形成。 GANT61 诱导人结肠癌细胞系早期 S 期 DNA 复制的抑制,导致涉及 ATM-Chk2 轴的 DNA 损伤信号传导并诱导细胞死亡。 GANT61 (30 μM) 导致急性髓系白血病 (AML) 细胞生长停滞和凋亡。激酶测定:在 10 cm 平板上用 GLI1 表达质粒以及报告质粒 12×GliBSLuc 和 R-Luc 转染 HEK293 细胞(第 0 天)。 24小时后,将细胞以每孔15,000个细胞的密度接种到底部透明的白色96孔板中。让细胞贴壁,并以终浓度为 10 μM 的 DMSO(0.5% DMSO 最终浓度)添加化合物(第 1.5 天)。细胞再生长 24 小时,随后裂解,然后使用双荧光素酶试剂盒进行分析。细胞测定:BrdU 掺入测定。在 5 μM 测试化合物(或 DMSO)存在下,在透明底部的白色 96 孔板中,将亚汇合细胞在减少的 FBS (2.5%) 中生长 48 小时。随后,用 BrdU 标记细胞 2 小时,固定并分析。
|
|
体内研究 (In Vivo) |
在注射 GLI1 阳性 22Rv1 前列腺癌细胞的裸鼠中,GANT61 会诱导生长衰退,直到摸不到肿瘤为止。在携带 SK-N-AS 神经母细胞瘤异种移植物的裸鼠中,GANT61 治疗(口服灌胃,50 mg/kg)在第 12 天显着抑制肿瘤生长,与对照组相比,肿瘤体积减少至 63%。
|
|
酶活实验 |
在 10 厘米平板上(第 0 天),用 GLI1 表达质粒以及报告质粒 12×GliBSLuc 和 R-Luc 转染 HEK293 细胞。 24 小时后,将细胞以每孔 15,000 个的密度接种到白色透明 96 孔板中。让细胞贴壁后(第 1.5 天),将化合物以 DMSO 中的终浓度为 10 μM(0.5% DMSO 最终浓度)添加到细胞中。细胞再生长二十四小时后,将其裂解并使用双荧光素酶试剂盒进行分析。
|
|
细胞实验 |
BrdU 掺入测定。在底部透明的白色 96 孔板上,亚汇合细胞在减少的 FBS (2.5%) 中生长 48 小时,同时暴露于 5 μM 测试化合物(或 DMSO)。然后将细胞固定,用 BrdU 标记两小时并进行检查。
|
|
动物实验 |
|
|
参考文献 |
分子式 |
C27H35N5
|
|
---|---|---|
分子量 |
429.6
|
|
精确质量 |
429.29
|
|
元素分析 |
C, 75.49; H, 8.21; N, 16.30
|
|
CAS号 |
500579-04-4
|
|
相关CAS号 |
|
|
外观&性状 |
White to off-white solid powder
|
|
SMILES |
CN(C)C1=CC=CC=C1CN2CCCN(C2C3=CC=NC=C3)CC4=CC=CC=C4N(C)C
|
|
InChi Key |
KVQOGDQTWWCZFX-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C27H35N5/c1-29(2)25-12-7-5-10-23(25)20-31-18-9-19-32(27(31)22-14-16-28-17-15-22)21-24-11-6-8-13-26(24)30(3)4/h5-8,10-17,27H,9,18-21H2,1-4H3
|
|
化学名 |
2-[[3-[[2-(dimethylamino)phenyl]methyl]-2-pyridin-4-yl-1,3-diazinan-1-yl]methyl]-N,N-dimethylaniline
|
|
别名 |
|
|
HS Tariff Code |
2934.99.9001
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 5 mg/mL (11.64 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (11.64 mM) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (11.64 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: 2.5 mg/mL (5.82 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 7: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 8: 2.5 mg/mL (5.82 mM) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 9: 5% DMSO+95% Corn oil: 30 mg/mL Solubility in Formulation 10: 8 mg/mL (18.62 mM) in Cremophor EL (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3277 mL | 11.6387 mL | 23.2775 mL | |
5 mM | 0.4655 mL | 2.3277 mL | 4.6555 mL | |
10 mM | 0.2328 mL | 1.1639 mL | 2.3277 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。